ContactReimbursement and Pricing of Pharmaceuticals and Pricing
Due to high demand, IGES experts have reissued the successful guide on the European reimbursement and pricing systems for pharmaceutical products. It also provides updated information on the harmonisation of the benefit assessment of new therapies at EU level. The new EU HTA process has been effective since January 2025 and is one of the most important projects in the field of European pharmaceutical regulation.
The English-language publication entitled ‘Reimbursement and Pricing of Pharmaceuticals in Europe’ is now in its seventh edition. It is aimed at anyone who is interested in the market launch and assessment of pharmaceutical innovations in Europe, particularly at professionals working in the areas of market authorization, market access and reimbursement at companies in the life science industry. Over the years, the publication has gained a broad readership and is in regular demand.
The 2025 edition takes a particularly in-depth look at the new, centralised Health Technology Assessment (HTA) in Europe, EU-HTA. The joint clinical evaluation of new medicines at EU level was launched on 1 January 2025 and is being implemented step by step. Getting ready for this is crucial for large and small pharmaceutical companies who aim to be successful in Europe. The guide explains the new procedure and points out the most important steps to follow.
The 73-page publication also provides a general overview of the respective authorisation, pricing and reimbursement systems of the five largest European countries: Germany, France, the UK, Italy and Spain. It also provides insights into HTA assessment in the UK, where a lively development can be observed after Brexit.
Numerous graphical illustrations facilitate understanding. Important market data and basic information on the social and healthcare systems of these top 5 countries are also provided.
The authors of the guide are pharmaceutical market experts from IGES Pharma, a division of the IGES Group that has been supporting research-based pharmaceutical manufacturers in the areas of market access, reimbursement and HTA for many years.
Print copies of the Guide ‘Reimbursement and Pricing of Pharmaceuticals in Europe’, can be requested here free of charge:
Contact: Agata Daroszewska
E-mail: agata.daroszewska@iges.com
Phone: +49-(0)30-23 08 09 0
